A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results

Kunz, P. L.; Kuo, Tai Chih; Kaiser, H. L.; Norton, Jeffrey A.; Longacre, Teri A.; Ford, JM; Fisher, George A.

doi:10.1200/jco.2008.26.15_suppl.15502

Cited by 20 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five other patients had advanced gastrointestinal NETs and the combination achieved partial response in one patient and stable disease in four patients [38]. Similarly, the combination of capecitabine with oxaliplatin and bevacizumab in 31 patients produced a 23% partial response rate with stable disease in 71% of the patients [39]. Similar objective responses have been noted with the combination of oxaliplatin with capecitabine alone [40].…”

Section: Treatment Of Well-differentiated Neuroendocrine Tumorssupporting

confidence: 52%

Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?

Narayanan

Kunz

2015

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are a group of biologically and clinically heterogeneous neoplasms that have varying degrees of responsiveness to systemic and targeted therapies. With recent advances in therapeutics, a number of biologic therapies have been incorporated into the management of NETs. In this review, we discuss the role of cytotoxic chemotherapy in the management of NETs with an overview of past and present clinical trials, current treatment guidelines and future directions.

show abstract

Section: Treatment Of Well-differentiated Neuroendocrine Tumorssupporting

confidence: 52%

Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?

Narayanan

Kunz

2015

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

show abstract

“…At the 2008 American Society of Clinical Oncology (ASCO) meeting, two phase II trials were reported with the combination of bevacizumab with oxaliplatin-based chemotherapy. The preliminary data showed promising activity both in carcinoids and islet cell carcinomas, obtaining 20-30% of partial responses (PR) and 60-80% SD [30,31]. The initial results of a phase II study with the combination of bevacizumab plus temozolomide were recently reported.…”

Section: Antiangiogenic Approachmentioning

confidence: 95%

Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors

Capdevila

Salazar

2009

Targ Oncol

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are rare neoplasms that require a multidisciplinary approach for an optimal management. The traditional cytotoxic agents are of limited efficacy in the treatment of these tumors. A better understanding of the molecular pathways that characterize tumor growth has provided novel targets in cancer treatment. Several proteins have been implicated as having a crucial role in GEPNETs. Several proangiogenic molecules are overexpressed in GEPNETs including vascular endothelial growth factor (VEGF) and its receptors, and related signaling pathway components such as epidermal growth factor receptor (EGFR), insulin growth factor-I receptor (IGF-IR) and PI3K-AKT-mTOR pathway. In this article we aim to review the recent development of the main molecules that target these proteins and have showed promising activity in the treatment of GEPNETs.

show abstract

“…Bevacizumab has also been combined with different chemotherapy regimens in small, phase II single-arm trials [84,85]. Although a synergistic effect appears to exist when combining bevacizumab and chemotherapy, results are not defi nitive.…”

Section: Bevacizumab In Gep-netsmentioning

confidence: 99%

Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)

et al. 2010

View full text Add to dashboard Cite

Neuroendocrine tumours (NET) of the digestive tract comprise a broad range of malignancies. The therapeutic approach to these tumours has not evolved as it did in other tumour types in the last two decades. The deeper knowledge of the underlying molecular biology behind the growth of neuroendocrine cells has brought much information to light. We now know that somatostatin analogues may not only be considered as symptomatic treatment but also as antitumour agents. Sunitinib, a tyrosine kinase (TK) inhibitor with antiangiogenic and antitumoural properties, has been shown to induce significant improvement in progression-free survival in a randomised trial conducted in well-differentiated pancreatic islet-cell NETs. The relevance of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway seems to be crucial in gastroenteropancreatic (GEP)-NETs. In fact, mTOR inhibitors have shown activity in uncontrolled trials, and large, randomised trial results will be available shortly. In this article, we summarise the most recent available data on medical therapy for GEPNETs.

show abstract

A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results

Cited by 20 publications

References 0 publications

Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?

Beyond Biologics: Is there a Role for Systemic Cytotoxic Chemotherapy in Neuroendocrine Tumors?

Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors

Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)

Contact Info

Product

Resources

About